Actinium Pharmaceuticals Welcomes Dr. Matt David as CFO to Enhance Leadership and Financial Strategy

Strengthening Leadership at Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. has recently made a significant move to enhance its leadership team by appointing Dr. Matt David, M.D. as the new Chief Financial Officer (CFO). This strategic decision marks a substantial advancement in the company's commitment to leading the field of targeted radiotherapies aimed at improving cancer treatment outcomes.

Dr. David steps into this crucial role with an impressive background that spans over two decades in the biopharmaceutical sector, primarily focusing on operating leadership, healthcare investment banking, and equity research. Prior to joining Actinium, he served as the Executive Vice President and Chief Business Officer at CorMedix Inc., where he played an instrumental role in achieving FDA approval for the company’s key product, DefenCath®, and led its successful commercial launch.

In his new capacity at Actinium, Dr. David will oversee various critical financial operations including finance, accounting, capital markets, and investor relations, also taking charge as the principal financial officer. His previous experiences as a public company CFO and interim CEO, combined with substantial dealings in strategic acquisitions and financial expertise, position him as a valuable asset to the organization. Sandesh Seth, Actinium's Chairman and CEO, expressed his enthusiasm about Dr. David's addition to the team, noting that his extensive experience aligns perfectly with the company's ambitions, particularly as it advances its pipeline projects, including ATNM-400, Actimab-A, and Iomab-ACT.

Dr. David elaborated on his enthusiasm for joining Actinium, emphasizing the company’s innovative approaches in developing targeted radiotherapy platforms, which he sees as pivotal in the evolving landscape of oncology drug development. With ongoing clinical studies, including the first-in-human study for ATNM-400, he highlighted the potential value drivers on the horizon for the company, expressing his commitment to positioning Actinium for further growth and success.

His earlier roles, including his history as Head of Strategy at Ovid Therapeutics Inc. and more than a decade in healthcare investment banking, equip him with a robust foundation in understanding both the scientific and financial elements crucial for a biopharmaceutical company. His educational background includes an M.D. from NYU School of Medicine and an undergraduate degree in Chemistry from Dartmouth College, further solidifying his expertise in the healthcare sector.

Actinium is lauded for its pioneering work in targeted radiotherapies, creating innovative solutions designed to enhance cancer patient outcomes while minimizing toxicity to healthy tissues. The company focuses on a biology-driven approach to develop differentiated radiopharmaceuticals, including promising projects aimed at solid tumors and hematologic malignancies.

As Actinium Pharmaceuticals steps forward with strengthened leadership under Dr. David, the company is poised to navigate the complexities of the biopharmaceutical industry, drive forward its innovative products, and ultimately enhance the lives of patients facing cancer. This leadership change signifies a forward-looking approach in a sector that continuously adapts to new challenges and opportunities.

For more information about Actinium Pharmaceuticals and its groundbreaking work, visit Actinium Pharmaceuticals.